RLN3

Across TCGA pan-cancer cohorts, RLN3 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RLN3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RLN3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RLN3 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

LUAD, LUSC, and KIRC are the cancer types where RLN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RLN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+0.717	<.001	6	view →
LUSC	Male	II,III,IV	−0.337	<.001	6	view →
KIRC	Male	All	+0.078	.034	3	view →
UCEC	All	IV	+0.285	.014	2	view →
LIHC	Male	All	+0.125	.021	2	view →
KICH	All	All	+0.507	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RLN3–LUAD

Open the LUAD breakdown →